Braftovi (encorafenib)
BRAFTOVI 50 MG Oral Capsule
NO BOXED WARNING
Dosage & Administration
Get Your Patient on Braftovi
See your patient's specific prior authorization requirements including coverage restrictions and step therapies
Or select your Insurance from the list below:
Braftovi Prescribing Information
Request Braftovi Samples
Learn More
Is my patient eligible for Braftovi samples?
- Your rep will communicate with you how to receive samples, when you can receive samples, the amount and more.
How do I find out who my Braftovi rep is?
- Not sure who your local Braftovi pharma rep is? Reach out to Array BioPharma Inc. and they can help you identify your rep.
Braftovi Prior Authorization Resources
Most recent state uniform prior authorization forms
Verified: Sep 24, 2024Arizona - Uniform Prior Authorization Form
Verified: Sep 24, 2024Colorado - Uniform Prior Authorization Form
Verified: Sep 24, 2024Hawaii - Uniform Prior Authorization Form
Verified: Sep 24, 2024Illinois - Uniform Prior Authorization Form
Verified: Sep 24, 2024Indiana - Uniform Prior Authorization Form
Verified: Sep 24, 2024Louisiana - Uniform Prior Authorization Form
Verified: Sep 24, 2024Minnesota - Uniform Prior Authorization Form
Verified: Sep 24, 2024New Hampshire - Uniform Prior Authorization Form
Verified: Sep 24, 2024New Mexico - Uniform Prior Authorization Form
Verified: Sep 24, 2024Oregon - Uniform Prior Authorization Form
Verified: Sep 24, 2024Texas - Uniform Prior Authorization Form
Verified: Oct 05, 2024Washington - Uniform Prior Authorization Form
Verified: Oct 05, 2024Wisconsin - Uniform Prior Authorization Form
Benefits investigation
Reimbursement help (FRM)
Braftovi Preferred Pharmacy
Braftovi Financial Assistance Options
Copay savings program
Learn More
Overview
- Reduce patient OOP costs for drug (and occasionally for drug administration/infusion costs or drug-related test costs)
Patient benefit
- A portion (or all) of patient OOP (deductible, copay), typically up to monthly and/or annual max
Patient eligibility
- Patient must enroll or activate (may permit HCPs to enroll on patient’s behalf for HCP-administered drugs)
- Generally, must have commercial insurance (rarely, may permit uninsured patients to use)
- May never be used with government insurance
How to sign up
- Cards may be downloadable digital cards or hard copies
- Some pharmacos offer debit cards with pre-loaded copay benefit
- Typically, available through multiple channels (e.g., rep to HCP to patient; pharmacy to patient; patient via website, Hub live agent, or copay vendor (live agent or IVR); patient and HCP via Hub enrollment form)
- Some HCP-administered product programs permit HCPs to enroll on a patient’s behalf through via Hub form
Foundation programs
Learn More
Overview
- Charitable 501(c)(3) organizations provide direct cost-sharing and other support (e.g., travel, counseling) through disease-state funds to indigent patients on first-come first-served basis
- These organizations may receive financial contributions from drug manaufacturers for particular disease-state funds that cannot provide funds directly to patients - the foundation must be independent/unaligned
Patient benefit
- Patients apply for grants that cover a portion (or all) of their out-of-pocket costs (deductibles and copays) until the grant is exhausted
Patient eligibility
- Patients must apply and meet eligibility criteria including income level (typically a multiple of federal poverty line), specific diagnosis, insurance status, etc.
How to sign up
- Patients submit proof of out-of-pocket drug costs to charities for reimbursement
Braftovi PubMed™ News
Braftovi Patient Education
To share resource; ask patient to:
1.Pull out phone
2.Open camera
3.Scan QR code with camera
4.Tap link
Patient toolkit
Pfizer Oncology Patient Access Guide - Spanish
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Open Camera on Phone
Scan QR Code & Tap Link
Braftovi FAQs
No, BRAFTOVI can cause fetal harm when administered to a pregnant woman. There are no available clinical data on its use during pregnancy. Animal studies showed developmental changes and abortifacient effects at doses greater than those used clinically. Pregnant women or females of reproductive potential should be informed of the potential risk to the fetus.
There are no data on the presence of BRAFTOVI in human milk. Due to potential serious adverse reactions in a breastfed child, women are advised not to breastfeed during BRAFTOVI treatment and for 2 weeks after the last dose.
In male rats, BRAFTOVI showed impacts on fertility at doses approximately 13 times the human exposure at the clinical dose. Males considering BRAFTOVI treatment should discuss potential impacts on fertility with their healthcare provider.
Females of reproductive potential should undergo pregnancy testing before starting BRAFTOVI. Effective contraception is advised during treatment and for 2 weeks after the last dose. Non-hormonal contraception methods are recommended due to potential interactions.
The safety and effectiveness of BRAFTOVI haven't been established in pediatric patients.
Clinical studies included elderly patients (aged 65 and older) with BRAF mutation-positive melanoma, metastatic CRC, and NSCLC. No significant differences in safety or effectiveness were observed between older and younger patients.
No dosage adjustment is recommended for patients with mild hepatic impairment. However, there's no established dosage for those with moderate or severe hepatic impairment.
No dosage adjustment is recommended for patients with mild to moderate renal impairment. There isn't a recommended dosage for those with severe renal impairment.
We receive information directly from the FDA and PrescriberPoint is updated as frequently as change are made available